Results 11 to 20 of about 58,915 (315)

Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study

BMC Cancer, 2021
Background Ipilimumab has shown long-term overall survival (OS) in patients with advanced melanoma in clinical trials, but robust real-world evidence is lacking.
Stéphane Dalle, Laurent Mortier, Pippa Corrie, Michal Lotem, Ruth Board, Ana María Arance, Frank Meiss, Patrick Terheyden, Ralf Gutzmer, Brian Buysse, Kelly Oh, Jane Brokaw, T. Kim Le, Susan D. Mathias, Julie Scotto, Jennifer Lord-Bessen, Andriy Moshyk, Srividya Kotapati, Mark R. Middleton   +18 more
doaj   +1 more source

Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma

Journal of Skin Cancer, 2021
Background. Checkpoint inhibitors are effective in the treatment of several types of cancer, either being used separately or in combination. Ipilimumab pioneered the treatment of metastatic melanoma, and nowadays, it has been used more frequently in ...
A. A. Formozo, J. R. Gomes, R. A. Schmerling, A. C. Buzaid   +3 more
doaj   +1 more source

Cost‐effectiveness of ipilimumab versus high‐dose interferon as an adjuvant therapy in resected high‐risk melanoma

Cancer Medicine, 2021
Background Adjuvant ipilimumab was found to improve the overall survival and reduce toxicity compared to high‐dose interferon (HDI) in patients with resected, high‐risk melanoma. However, the cost of ipilimumab is substantially higher than HDI.
Mia Salans, Patrick Travis Courtney, Anthony Yip, James D. Murphy   +3 more
doaj   +1 more source

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

Journal of Clinical Oncology, 2021
PURPOSE In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivolumab alone versus ipilimumab. Here, we report 6.5-year efficacy and safety outcomes.
J. Wolchok, V. Chiarion-Sileni, R. Gonzalez, J. Grob, P. Rutkowski, C. Lao, C. Cowey, D. Schadendorf, J. Wagstaff, R. Dummer, P. Ferrucci, M. Smylie, M. Butler, A. Hill, I. Márquez-Rodas, J. Haanen, M. Guidoboni, M. Maio, P. Schöffski, M. Carlino, C. Lebbé, G. McArthur, P. Ascierto, G. Daniels, G. Long, T. Bas, C. Ritchings, J. Larkin, F. Hodi   +28 more
semanticscholar   +1 more source

Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid Tumors

CPT: Pharmacometrics & Systems Pharmacology, 2020
Ipilimumab is a fully human monoclonal antibody approved for the treatment of melanoma as monotherapy and for the treatment of melanoma, renal cell carcinoma, and colorectal cancer in combination with nivolumab. Ipilimumab time‐varying clearance (CL) was
Kinjal Sanghavi, Jason Zhang, Xiaochen Zhao, Yan Feng, Paul Statkevich, Jennifer Sheng, Amit Roy, Heather E. Vezina   +7 more
doaj   +1 more source

Cost‐effectiveness of second‐line ipilimumab for metastatic melanoma: A real‐world population‐based cohort study of resource utilization

Cancer Medicine, 2023
Background The efficacy‐effectiveness gap between randomized trial and real‐world evidence regarding the clinical benefit of ipilimumab for metastatic melanoma (MM) has been well characterized by previous literature, consistent with initial concerns ...
Brandon Lu, Wei Fang Dai, Ruth Croxford, Wanrudee Isaranuwatchai, Jaclyn Beca, Ines B. Menjak, Teresa M. Petrella, Nicole Mittmann, Craig C. Earle, Scott Gavura, Rebecca E. Mercer, Timothy P. Hanna, Kelvin K. W. Chan   +12 more
doaj   +1 more source

The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis

World Journal of Surgical Oncology, 2020
Background Currently, nivolumab and ipilimumab are the most widely used immune checkpoint inhibitors. We performed a meta-analysis to evaluate the efficacy and treatment-related adverse events (TRAEs) of nivolumab plus ipilimumab therapy in cancer ...
Jingjie Chen, Shengnan Li, Qigu Yao, Nannan Du, Xiaojun Fu, Yuanmei Lou, Mengru Wang, Feiyan Mao, Danyi Mao, Parikshit Asutosh Khadaroo, Yingying Tang   +10 more
doaj   +1 more source

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.

New England Journal of Medicine, 2022
BACKGROUND Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable benefit.
M. Rohaan, T. H. Borch, J. H. van den Berg, Ö. Met, R. Kessels, M. G. Geukes Foppen, J. Stoltenborg Granhøj, B. Nuijen, C. Nijenhuis, I. Jedema, M. van Zon, Saskia Scheij, J. Beijnen, Marten Hansen, C. Voermans, I. M. Noringriis, T. Monberg, R. Holmstroem, L. Wever, M. V. VAN DIJK, L. Grijpink-Ongering, Ludy H.M. Valkenet, A. Torres Acosta, M. Karger, J. Borgers, Renske M T ten Ham, V. Retèl, W. V. van Harten, F. Lalezari, H. van Tinteren, A. V. D. van der Veldt, G. Hospers, Marion A. Stevense-den Boer, K. Suijkerbuijk, M. Aarts, D. Piersma, A. van den Eertwegh, J. D. de Groot, G. Vreugdenhil, E. Kapiteijn, M. Boers-Sonderen, W. Fiets, F. van den Berkmortel, E. Ellebaek, L. Hölmich, A. V. Van Akkooi, W. V. van Houdt, M. Wouters, J. V. van Thienen, C. Blank, A. Meerveld-Eggink, S. Klobuch, S. Wilgenhof, T. Schumacher, M. Donia, I. Svane, J. Haanen   +56 more
semanticscholar   +1 more source

Ipilimumab [PDF]

Drugs in R&D, 2010
Ipilimumab (BMS734016; MDX 101; MDX-010; MDX-CTLA-4; MDX-CTLA4) is an anti-CTLA-4 monoclonal antibody, which is in development by Medarex Inc. and Bristol-Myers Squibb as treatment for malignant melanoma, prostate cancer, lymphoma, and lung cancer. It is currently in phase III development for the melanoma and prostate cancer indications, and phase II ...
openaire   +2 more sources

Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)

Clinical and Translational Science, 2023
This analysis was conducted to inform dose selection of a combination of nivolumab plus ipilimumab for the treatment of sorafenib‐experienced patients with hepatocellular carcinoma (HCC).
Bruno Sangro, Thomas Yau, Anthony B. El‐Khoueiry, Masatoshi Kudo, Yun Shen, Marina Tschaika, Amit Roy, Yan Feng, Ling Gao, Urvi Aras   +9 more
doaj   +1 more source